Articles On Dimerix (ASX:DXB)

ASX lithium shares are bouncing on Thursday despite the lithium carbonate price trading at three-year lows and their peers in the materials sector lagging the market today. The S&P/ASX All Ordinaries Index (ASX: XAO) is up 0.75% whi...

ASX uranium shares are storming higher today. During the Thursday lunch hour, the All Ordinaries Index (ASX: XAO) is up a healthy 0.8%. And it's getting plenty of support from the uranium miners. Here's how these leading ASX uranium shares...

The S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. In early afternoon trade, the benchmark index is up a sizeable 0.7% to 8,043.7 points. Four ASX shares that are rising more than most today are listed below. Here's...

AML3D Ltd (ASX: AL3) shares are having a strong session on Thursday. In morning trade, the ASX defence stock is up 23% to 16 cents. Why is this ASX defence stock rocketing? Investors have been fighting to get hold of the 3D manufacturing so...

Dimerix Limited (ASX:DXB) has confirmed it’s begun recruiting adolescent kidney disease patients in Mexico, now that its ‘ACTION3‘ Phase 3 clinical trial location has been selected. Ages range from 12 to 17. HotCopper users were perusing...

  ASX falls on Wednesday with banks dragging down market Lithium stocks surge on CATL suspension reports; MinRes hits new high Energy stocks struggle as Brent drops below US$70   The ASX was on the back foot on Wednesday, down by 0.3%  w...

Many of Australia's top brokers have been busy adjusting their financial models and recommendations again. This has led to the release of a number of broker notes this week. Three ASX shares that brokers have named as buys this week are lis...

First patient completes Phase 3 trial and joins Open Label Extension study for its kidney disease drug candidate DMX-200 All patients from its ACTION3 Phase 3 clinical trial are eligible to receive the drug under the OLE Results from study...

Now could be a good time to buy Life360 Inc (ASX: 360) shares. That's the view of analysts at Goldman Sachs, which think the ASX 200 tech stock could deliver market-beating returns over the next 12 months. What is the broker saying about th...

On Tuesday, the S&P/ASX 200 Index (ASX: XJO) had a decent session and pushed higher. The benchmark index rose 0.3% to 8,011.9 points. Will the market be able to build on this on Wednesday? Here are five things to watch: ASX 200 expect...

The ASX200 closed up 0.3% at 8,012 points, just below its all time high set a few weeks ago. The local bourse climbed higher as both Commonwealth Bank and Macquarie broke share price records. The Energy sector surged nearly 1%, follow...

Argent Biopharma plans further trials of its cannabinoid-based epilepsy treatment  Argent’s early research work suggests “improved safety profile alongside enhanced efficacy.” The first patient in Dimerix’s pivotal kidney trial enters open...

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.6% to 8,034.2 points. Four ASX shares that have failed to follow the market higher today...

Dimerix chief Dr Nina Webster describes the three stages of drug development and the hurdles involved Dimerix is in phase III trials to treat a rare kidney condition Following promising interim analysis, further results are expected in mid...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX200 closed up half a percent at 7,971 points, as the market followed Wall Street’s strong lead. The IT sector lead the charge, up 1.62%, followed closely by Health Care 1.37% and Industrials 1.33%. The Energy sector lost 2% as the...

ASX health stocks rise 2% in past five days as broader markets lift 0.6% Morgans upgrades disinfectant device maker Nanosonics after positive trading update  Neuren receives rare paediatric disease designation from FDA for NNZ-2591 in Phel...

Mega ASX 200 iron ore shares BHP Group Ltd (ASX: BHP) and Fortescue Ltd (ASX: FMG) were the top two most traded ASX stocks last month among investors using the SelfWealth trading platform. Let's review the top 10. Top 10 most traded...

The 2024 Bioshares Biotech Summit being held in Fremantle from July 12-13 Morgans says conference likely to attract institutional and high net worth WA investors  Day one focus on new opportunities, finding the next blockbuster drug and re...

In this article, we examine the best ASX 200 healthcare shares of FY24 based on share price growth. Here are the best performers, according to data from S & P Global Market Intelligence. The top 3 ASX 200 healthcare shares of FY2...

On Thursday, the S&P/ASX 200 Index (ASX: XJO) had one of its best days of the year and stormed higher. The benchmark index rose 1.2% to 7,831.8 points. Will the market be able to build on this on Friday and end the week on a high? Her...

Singular Health receives $1 million investment from prominent crypto figure Craig Sellars  Adolescent recruitment into Dimerix’s ACTION3 Phase 3 trial to start after approval  Lumos inks deals for test distinguishing viral from bacterial i...

Women talk. But are we talking about the right things? Growing up in the 80s (I'm showing my age) my family didn't talk about finance, budgets or mortgages – I wish we had.  I finished school with no responsibilities. I had no outgoings...

The New Hope Corp Ltd (ASX: NHC) share price is taking a tumble today. Shares in the S&P/ASX 200 Index (ASX: XJO) coal miner closed yesterday trading for $5.26. In early afternoon trade on Thursday, shares are swapping hands for $5....

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 1% to 7,818.3 points. Four ASX shares that have failed to follow the market higher today are l...

A little-known ASX mining stock is setting the bar high these past two days. Very high. At market close on Tuesday shares in Waratah Minerals Ltd (ASX: WTM) – previously known as Battery Minerals Limited – closed trading for 12.5 cents...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Fancy grabbing a 917% one-year return from your ASX healthcare stock investment? Me too! The stock in question is clinical stage drug discovery and development company Dimerix Ltd (ASX: DXB) As you can likely guess by the phenomen...

Looking to invest in an ASX biotech share with the potential to become the next Telix Pharmaceuticals Ltd (ASX: TLX)? You're not alone! The S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company has been going from strength to st...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

ASX health stocks fall in past five days in line with broader markets as investors spooked by hotter than expected inflation Dimerix up 33% for week after inking second exclusive license deal for commercialisation of its Phase 3 kidney dis...

Dimerix (ASX:DXB) has announced an exclusive license agreement with Taiba Middle East for the commercialisation of its candidate DMX-200.

The ASX200 closed the day up 0.8%. All sectors bar one finished in the green. Real-estate lead the way, up 1.8%, tele-communications and staples followed, both gaining around 1.3%. The energy sector was the only sector to fall short,...

ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on  Rare Earths find at the Tundulu project in Malawi   Aussie shares rebounded pretty much across the boa...

The ASX200 is trading up around 0.7 per cent. Most sectors are in the green, real estate has gained the most so far, up nearly 1.6%. Staples follows, up 1.2%. The utilities and energy sectors are the only two to slip into the red....

Dimerix sells exclusive rights to register and commercialise DMX-200 for the treatment of kidney disease in key Middle East countries Dimerix to receive up to ~$120.5m from Taiba in upfront and milestone payments, plus royalties Second dea...

EMVision’s AI algorithm shows promise EMvision Medical Devices (ASX:EMV) has shared an update from its ongoing clinical trials focusing on improving EMVision’s AI algorithms for diagnosing strokes caused by bleeding or blockages in the brai...

Last Monday marked Clinical Trials Day, when the world’s healing profession celebrated the work of Royal Navy surgeon James Lind. The medical mariner was credited with carrying out the world’s first placebo-controlled clinical trial in 1747...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

The ASX has plunged alongside Wall Street on jitters of higher US rates for longer All 11 sectors closed in the red Uranium stocks gathered some ground today   The ASX200 has tumbled over 1% on Wednesday as hot US labour data sent jitters...

UK Regulatory Agency has given the greenlight for Dimerix’s DMX-200 Paediatric Investigation Plan The UK Paediatric Investigation Plan aims to ensure sufficient data is generated in Dimerix’s ACTION Phase 3 trial to allow for marketing app...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Morgans says economic challenges have been catalyst for innovation and resilience in ASX health sector PharmAust submits supplementary data to US FDA from Phase 1 MEND study in support of its ODD request Singular health gets $1 million bac...

Morgans says more money could flow into ASX healthcare sector in 2024 as higher interest rate cycle stabilises Nyrada soars after lead drug candidate demonstrates strong efficacy in reducing secondary brain injury in animal study   Dimerix...

Dimerix (ASX:DXB) has announced it has received firm commitments to raise $20 million via an institutional placement with proceeds to complete the ACTION3 Phase 3 clinical study in patients with debilitating kidney disease.

  Local markets gives up early gains, ekes out 0.1pc advantage IT and Utilities offset by Energy sector losses Small Caps led by RMI and Narryer Metals   We’re slightly higher at match out in Sydney. But big banks became bad banks after l...